Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol Oral Solution OLE in Rett Syndrome
NCT04252586Phase 3Terminated
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Feb 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of cannabidiol in Rett syndrome (RTT), sponsored by Jazz Pharmaceuticals plc. Started Feb 2020; status: terminated.
02
Drugs
cannabidiol
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT04252586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04252586.